Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 30 July 2012
The US Food and Drug Administration (FDA) on 30 July released new draft guidance aimed at reducing the variability and subjectivity of when premarket applications (PMAs) submitted to the Center for Devices and Radiological Health (CDRH) are deemed to be "administratively complete."
The draft guidance, Acceptance and Filing Review for Premarket Approval Applications, is particularly aimed at "assuring the consistency of our acceptance and filing decisions," FDA explained in its Federal Register notice.
The guidance, if adopted, would apply to both PMA's and panel-track PMA supplements reviewed at CDRH.
FDA said the newly redesigned process would, "provide a more efficient approach to ensuring that devices that have a reasonable assurance of safety and effectiveness reach patients as quickly as possible," by introducing two defined categories: acceptance criteria and filing criteria.
Acceptance criteria is characterized by a pre-review process in which FDA will notify an applicant if any administrative elements-are all sections accounted for, is the applicant's information complete, etc.-are missing from an application.
Filing decisions are looked at after a determination of administrative completeness is made, with CDRH officials checking the consistency of data relative to the protocol, final device design and proposed indications, among other considerations.
While the draft guidance does make some changes, FDA said it was "not significantly different" from an earlier 2003 guidance document of the same name. The largest change comes in the form of the differentiation of "filing review questions," which are now separated into the "acceptance" and "filing" criteria to better leverage agency resources and expedite the initial review process.
Comments on the draft guidance are due by 14 September 2012.
Read more:
Acceptance and Filing Review for Premarket Approval Applications
Tags: PMA Supplement Applications, PMA Applications, Administrative, Filing, Applications, Latest News, medical device
Regulatory Focus newsletters
All the biggest regulatory news and happenings.